^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    Source:
    NCCN
    Published date:
    09/15/2020
    Excerpt:
    Bevacizumab is not recommended for patients with squamous cell NSCLC.